| |
|
|
|
|
| Slide Lecture Programs |
| 2004 Core Curriculum |
Impact of vascular biology on cardiovascular disease, risk prevention, and treatment
Section IV: RAAS manipulation and cardiovascular risk |
August 27, 2004
|
| E: |
Risk reduction in diabetes: Focus on preclinical disease |
Slide 50 |
|
Download PowerPoint
|
LIFE: Comparison of treatment effects in overall population
vs patients with diabetes
- In the overall study population enrolled in the LIFE trial, the effects of losartan on the primary outcome were driven by a significant 25% reduction in stroke.1 Relative to atenolol, there were trends toward an increase in risk of MI and a decrease in risk of CV death.
- However, when the results of the diabetic cohort were analyzed, a different pattern emerged.2 As shown, there was a 37% reduction in risk of CV death (P = 0.028) and trends toward reduced risks of stroke (21% reduction, P = 0.204) and MI (17% risk reduction, P = 0.373).
1Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359:995-1003.
2Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Perdersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S, for the LIFE study group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet. 2002;359:1004-10.
|
|
|
Resources
